Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thymidine kinase from herpes simplex virus type 1 (HSV1-TK) is a viral enzyme encoded by the UL23 gene of HSV-1. It catalyzes the transfer of a phosphate group from ATP to thymidine, producing thymidine monophosphate (dTMP), essential for viral DNA replication. Unlike human TK1, HSV1-TK has broad substrate specificity, including pyrimidines, pyrimidine analogs (AZT), and purine/purine analogs such as acyclovir (ACV) and ganciclovir (GCV). It is used in antiviral therapy, suicide gene therapy for cancer, and as a reporter system.
Phosphorylation of nucleoside analogs to monophosphate form, leading to inhibition of viral DNA polymerase after further phosphorylation by cellular kinases.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thymidine Kinase from Herpes Simplex Virus Type 1 (HSV1-TK).